Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Proteomics in Acute Myeloid Leukemia: Current Applications in Precision Medicine and Targeted Immunotherapy.

Technology in cancer research & treatment·2026
Same author

The search for safe and effective CAR-T targets in AML.

Blood cancer journal·2026
Same author

RNA-based co-transfer of human CD8αβ with WT1-specific TCRαβ redirects tumor recognition by CD4 and γδ T-cells towards MHC class I-restricted WT1 epitopes and boosts CD8 T-cell responses with or without CD3 mRNA.

Experimental hematology & oncology·2026
Same author

Novel methods for the discovery of disease-associated T cell epitopes in autoimmunity.

Methods (San Diego, Calif.)·2026
Same author

Resilience of human tolerogenic dendritic cells to physiological oxygen supports clinical application: functional stability amidst glycolytic and differentiation shifts.

Experimental hematology & oncology·2026
Same author

Comparative Efficacy of Talquetamab vs. Real-World Physician's Choice of Treatment in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma: Updated Analyses of MonumenTAL-1 vs. LocoMMotion/MoMMent.

Advances in therapy·2025

Related Experiment Video

Updated: Jun 21, 2026

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
12:43

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

Dendritic cell-based cancer gene therapy.

Evelien L J M Smits1, Sébastien Anguille, Nathalie Cools

  • 1Laboratory of Experimental Hematology, Vaccine and Infectious Disease Institute (VAXINFECTIO), University of Antwerp, B-2610 Wilrijk (Antwerp), Belgium.

Human Gene Therapy
|August 7, 2009
PubMed
Summary
This summary is machine-generated.

Gene-modified dendritic cells (DCs) offer a promising cancer therapy approach. Engineering DCs to express tumor antigens and immune-boosting molecules enhances their potential for effective cancer regression.

More Related Videos

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
08:40

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

Related Experiment Videos

Last Updated: Jun 21, 2026

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
12:43

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
08:40

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

Area of Science:

  • Immunology
  • Oncology
  • Biotechnology

Background:

  • Dendritic cells (DCs) are potent antigen-presenting cells crucial for initiating immune responses.
  • Current DC-based cancer therapies show promise but have limited clinical success in inducing tumor regression.
  • Advancements in understanding DC biology offer new strategies for optimizing therapeutic protocols.

Purpose of the Study:

  • To review gene delivery systems and transgenes for modifying dendritic cells (DCs).
  • To explore the potential of gene-modified DCs for enhancing cancer immunotherapy.
  • To highlight future strategies for DC-based therapies targeting complex immune responses.

Main Methods:

  • Review of existing literature on gene delivery systems for DCs.
  • Analysis of various transgenes used for genetic modification of DCs.
  • Compilation of data from clinical trials using gene-modified DCs.

Main Results:

  • Gene-modified DCs can express full-length tumor-associated antigens (TAAs) for MHC class I and II presentation.
  • Genetic modification can enhance DC immunogenicity by expressing immune-potentiating molecules or downregulating negative regulators.
  • Previous trials demonstrated tumor-specific immune responses with low toxicity, but modest cancer regression rates.

Conclusions:

  • Gene-modified DCs represent a significant advancement in DC-based cancer therapy.
  • These engineered DCs offer a more robust approach to TAA presentation and immune stimulation compared to peptide vaccines.
  • Future strategies should focus on multi-layered immune response modulation for improved therapeutic outcomes.